PhRMA reports lists 547 neurological drugs in development

News
Article

PhRMA releases report on neurological drugs in development and Hispanics would benefit most from these products.

The Pharmaceutical Research and Manufacturers of America (

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
Related Content
FDA Accepts GSK's BLA for 5-in-1 Meningococcal Vaccine

FDA Accepts GSK's BLA for 5-in-1 Meningococcal Vaccine

April 16th 2024
Article

The company’s investigational ABCWY vaccine candidate will be reviewed by the FDA by February 14, 2025.

Looking to the Future of Independent Pharmacy

Looking to the Future of Independent Pharmacy

July 13th 2022
Podcast

Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.

FDA: Fasenra Approved As Add-On Maintenance Therapy for Severe Pediatric Asthma

FDA: Fasenra Approved As Add-On Maintenance Therapy for Severe Pediatric Asthma

April 12th 2024
Article

Fasenra was initially approved in 2017 as an add on maintenance therapy in patients aged 12 years and older.

Podcast: Pharmacy Financing With First Financial Bank

Podcast: Pharmacy Financing With First Financial Bank

January 28th 2022
Podcast

Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.

FDA Approves Iloperidone for Acute Treatment of Manic, Mixed Episodes in Bipolar I

FDA Approves Iloperidone for Acute Treatment of Manic, Mixed Episodes in Bipolar I

April 4th 2024
Article

The drug was previously approved in 2009 to treat schizophrenia.

FDA Clears First Digital Therapeutic to Treat Major Depressive Disorder

FDA Clears First Digital Therapeutic to Treat Major Depressive Disorder

April 2nd 2024
Article

Rejoyn from Otsuka Pharmaceutical and Click Therapeutics is a 6-week program that helps enhance cognitive control of emotions through brief therapy lessons and training exercises.

© 2024 MJH Life Sciences

All rights reserved.